These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 36636644)

  • 1. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
    Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
    Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.
    Zhu X; Hu H; Xiao Y; Li Q; Zhong Z; Yang J; Zou P; Cao Y; Meng F; Li W; You Y; Guo AY; Zhu X
    Cancer Lett; 2022 Jun; 536():215668. PubMed ID: 35367518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.
    Ukrainskaya VM; Musatova OE; Volkov DV; Osipova DS; Pershin DS; Moysenovich AM; Evtushenko EG; Kulakovskaya EA; Maksimov EG; Zhang H; Rubtsov YP; Maschan MA; Stepanov AV; Gabibov AG
    Sci Rep; 2023 Jan; 13(1):463. PubMed ID: 36627334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
    Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
    PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
    Ren CX; Chen XX; Zhao L; Tian Y; Xu KL; Zhao K
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):506-512. PubMed ID: 35968595
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
    Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
    Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer.
    Aharon A; Horn G; Bar-Lev TH; Zagagi Yohay E; Waks T; Levin M; Deshet Unger N; Avivi I; Globerson Levin A
    Hum Gene Ther; 2021 Oct; 32(19-20):1224-1241. PubMed ID: 34494460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.
    Yang LR; Li L; Meng MY; Wang WJ; Yang SL; Zhao YY; Wang RQ; Gao H; Tang WW; Yang Y; Yang LL; Liao LW; Hou ZL
    J Cell Mol Med; 2021 Jan; 25(2):686-700. PubMed ID: 33225580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells.
    Storci G; De Felice F; Ricci F; Santi S; Messelodi D; Bertuccio SN; Laprovitera N; Dicataldo M; Rossini L; De Matteis S; Casadei B; Vaglio F; Ursi M; Barbato F; Roberto M; Guarino M; Asioli GM; Arpinati M; Cortelli P; Maffini E; Tomassini E; Tassoni M; Cavallo C; Iannotta F; Naddeo M; Tazzari PL; Dan E; Pellegrini C; Guadagnuolo S; Carella M; Sinigaglia B; Pirazzini C; Severi C; Garagnani P; Kwiatkowska KM; Ferracin M; Zinzani PL; Bonafè M; Bonifazi F
    J Clin Invest; 2024 Jun; 134(14):. PubMed ID: 38833312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 14. CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity.
    Kim JI; Park MY; Kwon E; Kang HJ; Kang BC
    Toxicol Appl Pharmacol; 2023 Sep; 475():116628. PubMed ID: 37506978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
    Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
    J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.
    Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
    Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
    Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Chantarat N; Pe KCS; Suppipat K; Vimolmangkang S; Tawinwung S
    Cannabis Cannabinoid Res; 2024 Jun; 9(3):819-829. PubMed ID: 37878339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.